

EUROPEAN CURRICULUM VITAE FORMAT



PERSONAL INFORMATION

Name	BERGAMO FRANCESCA
Address	ISTITUTO ONCOLOGICO VENETO MEDICAL ONCOLOGY 1 UNIT VIA GATTAMELATA 64 35128 PADOVA, ITALY
Telephone	+39-049-8215953
Fax	+39-049-8215900
E-mail	francesca.bergamo@ioveneto.it
Nationality	Italian
Date of birth	AUGUST 20 TH , 1981

WORK EXPERIENCE

• Dates (from – to) • Name and address of employer • Type of business or sector • Occupation or position held	January 2015 - ongoing Medical Oncology 1 Unit Istituto Oncologico Veneto, IRCCS, Padova Public Hospital Full time Consultant Oncologist (Dirigente Medico I livello)
• Dates (from – to) • Name and address of employer • Type of business or sector • Occupation or position held • Main activities and responsibilities	October 2011 - December 2014 Medical Oncology 1 Unit Istituto Oncologico Veneto, IRCCS, Padova Public Hospital Freelance Medical Oncologist with fixed-term contract Medical Treatment of Cancer Patients and research activity in gastrointestinal cancer
• Dates (from – to) • Name and address of employer • Type of business or sector • Occupation or position held • Main activities and responsibilities	August 2011 – September 2011 Medical Oncology 1 Unit Istituto Oncologico Veneto, IRCCS, Padova Public Hospital Research Fellow (post-specialization) Medical Treatment of Cancer Patients and research project on colorectal cancer.
• Dates (from – to) • Name and address of employer • Type of business or sector • Occupation or position held • Main activities and responsibilities	November 2012 – February 2013 Medical Oncology Azienda Ospedaliero Universitaria Pisana - Pisa (AIOM award for young oncologist) Public Hospital Fellow Translational project "BRAF mutation in liver resected metastatic colorectal cancer patients", clinical and research activity.
• Dates (from – to) • Name and address of employer • Type of business or sector • Occupation or position held	July 2007 – July 2011 Medical Oncology Istituto Oncologico Veneto, IRCCS, Padova Public Hospital Resident in Medical Oncology

Page 1 - Curriculum vitae of
[Bergamo Francesca]

For more information go to
www.cedefop.eu.int/transparency/
europa.eu.int/comm/education/index_en.html
eurescvsearch.com/

- Main activities and responsibilities

Assistant in Medical Treatment of Cancer Patients and clinical research in solid tumors

RESEARCH EXPERIENCE

- Dates (from – to)
- Name and address of Organization
 - Occupation or position held
- Main activities and responsibilities

2007- present
Industry Sponsored Trials or non- sponsored Academic trials

Co-Investigator or principal investigator in more than 60 trials (Industry-sponsored or Academic) dealing with colorectal cancer, bilio-pancreatic cancer, gastric cancer, hepatocellular carcinoma, elderly patients and palliative cares

EDUCATION AND TRAINING

- Dates (from – to)
- Name and type of organisation providing education and training
 - Principal subjects/occupational skills covered
 - Title of qualification awarded

2011
Residency School in Medical Oncology
University of Padova
Medical management and molecular basis of solid tumors

Medical Oncology Specialty

- Dates (from – to)
- Name and type of organisation providing education and training
 - Principal subjects/occupational skills covered
 - Title of qualification awarded

2006
University of Padova

Medicine

Degree in Medicine (M.D.- Medical Doctor)

PERSONAL SKILLS AND COMPETENCES

*Acquired in the course of life and career
but not necessarily covered by formal
certificates and diplomas.*

MOTHER TONGUE

ITALIAN

OTHER LANGUAGES

- Reading skills
- Writing skills
- Verbal skills

ENGLISH

EXCELLENT
VERY GOOD
VERY GOOD

ORGANISATIONAL SKILLS AND COMPETENCES

*Coordination and administration of people,
projects and budgets; at work, in voluntary
work (for example culture and sports) and at
home, etc.*

MANAGEMENT OF CANCER PATIENTS WITHIN MULTIDISCIPLINARY TEAMS
WRITING OF RESEARCH PROJECTS
CONDUCTION OF CLINICAL TRIALS (PHASE II, III AND IV) AS CO-INVESTIGATOR OR PRINCIPAL
INVESTIGATOR ACCORDING TO GCP TRAINING

TECHNICAL SKILLS AND COMPETENCES

*With computers, specific kinds of equipment,
machinery, etc.*

OFFICE PACKAGE
RESEARCHES IN PUBLIC DATABASES

Scientific Publications

Scientific Publications:

- 1) Koussis H, Scola A, **Bergamo F**, Tonello S, Basso U, Karahontzitis P, Chiarion-Sileni V, Pasetto L, Ruol A, Loreggian L, Lora O, Bottin R, Marioni G, Donach M, Jirillo A. Neoadjuvant carboplatin and vinorelbine followed by chemoradiotherapy in locally advanced head and neck or oesophageal squamous cell carcinoma: a phase II study in elderly patients or patients with poor performance status. *Anticancer Res.* 2008 Mar-Apr;28(2B):1383-8.
- 2) Aschele C, **Bergamo F**, Lonardi S. Chemotherapy for operable and advanced colorectal cancer. *Cancer Treat Rev.* 2009 Oct;35(6):509-16. Epub 2009 May 29.
- 3) Cappetta A, **Bergamo F**, Mescoli C, Lonardi S, Rugge M, Zagonel V. Hepatoid adenocarcinoma of the colon: what should we target? *Pathol Oncol Res.* 2012 Jan;18(1):93-6. doi: 10.1007/s12253-011-9424-5. Epub 2011 Jun 12.
- 4) Cappetta A, Lonardi S, Pastorelli D, **Bergamo F**, Lombardi G, Zagonel V. Advanced gastric cancer (GC) and cancer of the gastro-oesophageal junction (GEJ): focus on targeted therapies. *Crit Rev Oncol Hematol.* 2012 Jan;81(1):38-48.
- 5) Argyriou AA, Cavaletti G, Briani C, Velasco R, Bruna J, Campagnolo M, Alberti P, **Bergamo F**, Cortinovis D, Cazzaniga M, Santos C, Papadimitriou K, Kalofonos HP. Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer. *Cancer.* 2013 Jan 15;119(2):438-44.
- 6) Briani C, Campagnolo M, Lucchetta M, Cacciavillani M, Dalla Torre C, Granata G, **Bergamo F**, Lonardi S, Zagonel V, Cavaletti G, Ermani M, Padua L. Ultrasound assessment of oxaliplatin-induced neuropathy and correlations with neurophysiologic findings. *Eur J Neurol.* 2013 Jan;20(1):188-92.
- 7) Lucchetta M, Lonardi S, **Bergamo F**, Alberti P, Velasco R, Argyriou AA, Briani C, Bruna J, Cazzaniga M, Cortinovis D, Cavaletti G, Kalofonos HP. Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer. *Cancer Chemother Pharmacol.* 2012 Dec;70(6):899-902.
- 8) Fomaro L, Lonardi S, Masi G, Loupakis F, **Bergamo F**, Salvatore L, Cremolini C, Schirripa M, Vivaldi C, Aprile G, Zaniboni A, Bracarda S, Fontanini G, Sensi E, Lupi C, Morvillo M, Zagonel V, Falcone A. FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). *Ann Oncol.* 2013 Aug; 24(8):2062-7.
- 9) Reni M, Cereda S, Milella M, Novarino A, Passardi A, Mambrini A, Di Lucca G, Aprile G, Belli C, Danova M, **Bergamo F**, Franceschi E, Fugazza C, Ceraulo D, Villa E. Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: A phase II randomised trial. *Eur J Cancer.* 2013 Jul 27. doi:pii: S0959-8049(13)00545-5. 10.1016/j.ejca.2013.06.041.
- 10) Campagnolo M, Lazzarini D, Fregona I, Cacciavillani M, **Bergamo F**, Parrozzani R, Midena E, Briani C. Corneal confocal microscopy in patients with oxaliplatin-induced peripheral neuropathy. *J Peripher Nerv Syst.* 2013 Sep;18(3):269-71.
- 11) Loupakis F, Cremolini C, Salvatore L, Masi G, Sensi E, Schirripa M, Michelucci A, Pfanner E, Brunetti I, Lupi C, Antoniotti C, **Bergamo F**, Lonardi S, Zagonel V, Simi P, Fontanini G, Falcone A. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. *Eur J Cancer.* 2013 Oct 15. pii: S0959-8049(13)00840-X.
- 12) **Bergamo F**, Maruzzo M, Basso U, Montesco MC, Zagonel V, Gringeri E, Cillo U. Neoadjuvant sirolimus for a large hepatic perivascular epithelioid cell tumor (PEComa). *World J Surg Oncol.* 2014 Feb 27 ;12 :46.
- 13) Fomaro L, Cereda S, Aprile G, Di Girolamo S, Santini D, Silvestris N, Lonardi S, Leone F, Milella M, Vivaldi C, Belli C, **Bergamo F**, Lutrino SE, Filippi R, Russano M, Vaccaro V, Brunetti AE, Rotella V, Falcone A, Barbera MA, Corbelli J, Fasola G, Aglietta M, Zagonel V, Reni M, Vasile E, Brandi G. Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. *Br J Cancer.* 2014 Apr 8. DOI: 10.1038/BJC.2014.190.

- 14) Bajetta E, Floriani I, Di Bartolomeo M, et al. for the ITACA-S (Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach trial) Study Group. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. *Ann Oncol*. 2014 Apr 12.
- 15) Schirripa M, Cremolini C, Loupakis F, Morvillo M, **Bergamo F**, Zoratto F, Salvatore L, Antoniotti C, Marmorino F, Sensi E, Lupi C, Fontanini G, De Gregorio V, Giannini R, Basolo F, Masi G, Falcone A. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. *Int J Cancer*. 2015 Jan 1;136(1):83-90.
- 16) Zulato E, **Bergamo F**, De Paoli A, Griguolo G, Esposito G, De Salvo GL, Mescoli C, Rugge M, Nardin M, Di Grazia L, Lonardi S, Indraccolo S, Zagonel V. Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab. *Br J Cancer*. 2014 Jul 8;111(1):25-32.
- 17) Ruzzo A, Graziano F, Galli F, Giacomini E, Floriani I, Galli F, Rulli E, Lonardi S, Ronzoni M, Massidda B, Zagonel V, Pella N, Mucciarini C, Labianca R, Ionta MT, Veltri E, Sozzi P, Barni S, Ricci V, Foltran L, Nicolini M, Biondi E, Bramati A, Turci D, Lazzarelli S, Verusio C, **Bergamo F**, Sobrero A, Frontini L, Magnani M. Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients. *Sci Rep*. 2014 Nov 5;4:6828.
- 18) Briani C, Argyriou AA, Izquierdo C, Velasco R, Campagnolo M, Alberti P, Frigeni B, Cacciavillani M, **Bergamo F**, Cortinovis D, Cazzaniga M, Bruna J, Cavaletti G, Kalofonos HP. Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study. *J Peripher Nerv Syst*. 2014 Dec;19(4):299-306.
- 19) Lutrino SE, **Bergamo F**, Schirripa M, Rosati G, Avallone A, Giampieri R, Cordio S, Berretta M, Limpe FR, Pisa FE, Lonardi S, Loupakis F, Fasola G, Aprile G. Bevacizumab and First-line Chemotherapy for Older Patients with Advanced Colorectal Cancer: Final Results of a Community-based Observational Italian Study. *Anticancer Res*. 2015 Apr;35(4):2391-9.
- 20) Schirripa M, **Bergamo F**, Cremolini C, Casagrande M, Lonardi S, Aprile G, Yang D, Marmorino F, Pasquini G, Sensi E, Lupi C, De Maglio G, Borrelli N, Pizzolitto S, Fasola G, Bertorelle R, Rugge M, Fontanini G, Zagonel V, Loupakis F, Falcone A. BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection. *Br J Cancer*. 2015 Jun 9;112(12):1921-8.
- 21) Pietrantonio F, Aprile G, Rimassa L, Franco P, Lonardi S, Cremolini C, Biondani P, Sbicego EL, Pasqualetti F, Tomasello G, Nigam M, Casagrande M, Ghidini M, Muni R, Montrone S, **Bergamo F**, Berenato R, Fontanella C, Bozzarelli S, Moretto R, Battaglin F, Di Bartolomeo M, de Braud F, Miceli R. A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer. *Radiother Oncol*. 2015 Nov;117(2):315-21.
- 22) Schirripa M, Loupakis F, Lonardi S, Cremolini C, **Bergamo F**, Zagonel V, Falcone A. Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer. *Ann Oncol*. 2015 Dec;26(12):2503.
- 23) Pietrantonio F, Cremolini C, Aprile G, Lonardi S, Orlandi A, Mennitto A, Berenato R, Antoniotti C, Casagrande M, Marsico V, Marmorino F, Cardellino GG, **Bergamo F**, Tomasello G, Formica V, Longarini R, Giommoni E, Caporale M, Di Bartolomeo M, Loupakis F, de Braud F. Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope. *Oncologist*. 2015 Nov;20(11):1261-5.
- 24) Cremolini C, Loupakis F, Masi G, Lonardi S, Granetto C, Mancini ML, Chiara S, Moretto R, Rossini D, Vitello S, Allegrini G, Tonini G, **Bergamo F**, Tomasello G, Ronzoni M, Buonadonna A, Bustreo S, Barbara C, Boni L, Falcone A. FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials. *Ann Oncol*. 2016 Feb 9.
- 25) Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, **Bergamo F**, Zagonel V, Leone F, Depetris I, Martinelli E, Troiani T, Ciardiello F, Racca P, Bertotti A, Siravegna G, Torri V, Amatu A, Ghezzi S, Marrapese G, Palmeri L, Valtorta E, Cassingena A, Lauricella C, Vanzulli A, Regge D, Veronese S, Comoglio PM, Bardelli A, Marsoni S, Siena S. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. *Lancet Oncol*. 2016 Apr 20.
- 26) Aprile G, Ferrari L, Cremolini C, **Bergamo F**, Fontanella C, Battaglin F, Rihawi K, Lonardi S, Loupakis F, Scartozzi M. Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies. *Expert Rev Clin Pharmacol*. 2016 Jul;9(7):877-85.
- 27) Moretto R, Cremolini C, Rossini D, Pietrantonio F, Battaglin F, Mennitto A, **Bergamo F**, Loupakis F, Marmorino F, Berenato R, Marsico VA, Caporale M, Antoniotti C, Masi G, Salvatore L, Borelli B, Fontanini G, Lonardi S, De Braud F, Falcone A. Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal

- 28) Dreussi E, Cecchin E, Polesel J, Canzonieri V, Agostini M, Boso C, Belluco C, Buonadonna A, Lonardi S, **Bergamo F**, Gagno S, De Mattia E, Pucciarelli S, De Paoli A, Toffoli G. Pharmacogenetics Biomarkers and Their Specific Role in Neoadjuvant Chemoradiotherapy Treatments: An Exploratory Study on Rectal Cancer Patients. *Int J Mol Sci*. 2016 Sep 5;17(9).
- 29) Cremolini C, Casagrande M, Loupakis F, Aprile G, **Bergamo F**, Masi G, Moretto R R, Pietrantonio F, Marmorino F, Zucchelli G, Tomasello G, Tonini G, Allegri G, Granetto C, Ferrari L, Urbani L, Cillo U, Pilati P, Sensi E, Pellegrinelli A, Milione M, Fontanini G, Falcone A. Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest. *Eur J Cancer*. 2017 Mar;73:74-84.
- 30) Ferrarese A, **Bergamo F**, Calabrese F, Girolami B, Iovino S, Lonardi S, Nannini N, Vio S, Zola E, Vianello A, Baggio G. An untreatable dyspnoea: more defendants under investigation. *Intern Emerg Med*. 2017 Feb 14.

Scientific affiliations

ITALIAN ASSOCIATION OF MEDICAL ONCOLOGY-**AIOM**
EUROPEAN SOCIETY OF MEDICAL ONCOLOGY-**ESMO**
AMERICAN SOCIETY OF CLINICAL ONCOLOGY-**ASCO**

Awards

2012 - AIOM AWARD FOR YOUNG ONCOLOGIST FOR THE TRANSLATIONAL RESEARCH PROJECT "*BRAF MUTATION IN LIVER RESECTED METASTATIC COLORECTAL CANCER PATIENTS*".

Autorizzo il trattamento dei miei dati personali ai sensi del DL. 30 GIUGNO 2003, N° 196 "CODICE IN MATERIA DI PROTEZIONE DEI DATI PERSONALI".

PADUA, 15 APRIL 2017